A novel imatinib analogue inhibitor of chronic myeloid leukaemia: design, synthesis and characterization—explanation of its folded conformation
Chronic myeloid leukaemia (CML) is primarily treated using imatinib mesylate, a tyrosine kinase inhibitor (TKI) targeting the BCR::ABL1 oncoprotein. However, the development of drug resistance and adverse side effects necessitate the exploration of alternative therapeutic agents. This study presents...
Збережено в:
| Автори: | , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
The Royal Society
2025-01-01
|
| Серія: | Royal Society Open Science |
| Предмети: | |
| Онлайн доступ: | https://royalsocietypublishing.org/doi/10.1098/rsos.241654 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
